Autophagy in Hepatocytes in Infants With Alpha-1 ATD and Different Liver Disease Outcomes: A Retrospective Analysis

Elżbieta Czarnowska1, Agnieszka Bakuła, Joanna B Bierła

  • 1*Department of Pathology †Department of Gastroenterology, Hepatology Nutrition Disorders and Paediatrics, The Children's Memorial Health Institute ‡Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland.

Insights

Infants with Alpha-1-Antitrypsin Deficiency (α1ATD) and unfavorable liver outcomes show low Parkin expression and mitochondrial abnormalities in infancy. These findings may predict poor liver disease prognosis in α1ATD patients.

Area of Science:

  • Hepatology
  • Genetics
  • Cell Biology

Background:

  • Alpha-1-Antitrypsin Deficiency (α1ATD) is a genetic disorder.
  • The PiZZ phenotype (ATZ) is the most common and severe form of α1ATD.
  • Liver disease is a major complication of ATZ, but early predictors are lacking.

Purpose of the Study:

  • To investigate liver-specific pathways for antitrypsin (AT) protein disposal in infants with ATZ.
  • To determine if early cellular changes in infancy are associated with unfavorable liver outcomes in ATZ.

Main Methods:

  • Liver samples from infants with ATZ (unfavorable and good outcomes) and biliary atresia (control) were analyzed.
  • Autophagy activity was assessed via mRNA and protein expression (Calnexin, Beclin-1, p62, Parkin).
  • Hepatocyte ultrastructure was examined using morphometric analyses.

Main Results:

  • No significant differences in liver gene expression were found between ATZ groups.
  • Parkin immunohistochemical expression differed between ATZ groups, with lower expression in unfavorable outcomes.
  • Hepatocytes in infants with unfavorable ATZ outcomes showed low Parkin, isolated mitophagosomes, and enlarged mitochondria.

Conclusions:

  • Specific infant cellular features, including low Parkin expression, may indicate a predisposition to poor liver outcomes in ATZ.
  • Low Parkin expression could serve as a prognostic marker for liver disease in α1ATD.
  • Further research with larger cohorts is necessary to validate these findings for disease prognosis and treatment.
Abstract

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
6.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.6K